Four-year safety follow-up of the tetravalent dengue vaccine CYD-TDV

被引：6
|
作者：
Wilder-Smith, A. [1 ,2 ]
机构：
[1] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore
[2] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2018年 / 24卷 / 07期
关键词：
CYD-TDV; Dengue; Safety follow-up; Tetravalent dengue vaccine; Vaccine;
D O I：
10.1016/j.cmi.2018.03.024
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：680 / 681
页数：2
相关论文
共 45 条
  • [41] Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study
    Hosain, Romana
    Aquino, Peter
    Baccarini, Carmen
    Smolenov, Igor
    Li, Ping
    Qin, Haijing
    Verhoeven, Carole
    Hu, Branda
    Huang, Yung
    Rubio, Pilar
    VACCINE, 2023, 41 (13) : 2253 - 2260
  • [42] Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up
    Salehi, Mohammadreza
    Darazam, Ilad Alavi
    Nematollahi, Alireza
    Alimohammadi, Masoumeh
    Pouya, Sedigheh
    Alimohammadi, Reza
    Khajavirad, Nasim
    Porgoo, Meysam
    Sedghi, Mosslim
    Sepahi, Mohammad Mahdi
    Azimi, Maryam
    Hosseini, Hamed
    Hashemi, Seyed Mahmoud
    Dehghanizadeh, Somaye
    Khoddami, Vahid
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134
  • [43] Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study
    Grenfell, Rafaella F. Q.
    Almeida, Nathalie B. F.
    Filgueiras, Priscilla S.
    Corsini, Camila A.
    Gomes, Sarah V. C.
    de Miranda, Daniel A. P.
    Lourenco, Adelina J.
    Martins-Filho, Olindo A.
    de Oliveira, Jaquelline G.
    Teixeira-Carvalho, Andrea
    Campos, Guilherme R. F.
    Nogueira, Mauricio L.
    Alves, Pedro Augusto
    Fernandes, Gabriel R.
    Castilho, Leda R.
    Lima, Tulio M.
    de Abreu, Daniel P. B.
    Alvim, Renata G. F.
    Silva, Thais Barbara de S.
    Jeremias, Wander de J.
    Otta, Dayane A.
    Campi-Azevedo, Ana Carolina
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [44] Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
    Khairullin, Berik
    Zakarya, Kunsulu
    Orynbayev, Mukhit
    Abduraimov, Yergali
    Kassenov, Markhabat
    Sarsenbayeva, Gulbanu
    Sultankulova, Kulyaisan
    Chervyakova, Olga
    Myrzakhmetova, Balzhan
    Nakhanov, Aziz
    Nurpeisova, Ainur
    Zhugunissov, Kuandyk
    Assanzhanova, Nurika
    Nurabayev, Sergazy
    Kerimbayev, Aslan
    Yershebulov, Zakir
    Burashev, Yerbol
    Kulmagambetov, Ilyas
    Davlyatshin, Timur
    Sergeeva, Maria
    Buzitskaya, Zhanna
    Stukova, Marina
    Kutumbetov, Lespek
    ECLINICALMEDICINE, 2022, 50
  • [45] Long-term persistence of immune response to the AS04-adjuvanted HPV-16/18 vaccine in Chinese girls aged 9-17 years: Results from an 8-9-year follow-up phase III open-label study
    Hu, Yuemei
    Zhang, Xiang
    He, Yilin
    Ma, Zhilong
    Xie, Yan
    Lu, Xiangbin
    Xu, Yabin
    Zhang, Yanqiu
    Jiang, Yunyu
    Xiao, Hui
    Struyf, Frank
    Folschweiller, Nicolas
    Jiang, Johny
    Poncelet, Sylviane
    Karkada, Naveen
    Jastorff, Archana
    Borys, Dorota
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 392 - 399
12345